




Cite this article: Ruffieux Y et al (2021). The
treatment gap for mental disorders in adults
enrolled in HIV treatment programmes in
South Africa: a cohort study using linked
electronic health records. Epidemiology and
Psychiatric Sciences 30, e37, 1–11. https://
doi.org/10.1017/S2045796021000196
Received: 22 October 2020
Revised: 4 March 2021
Accepted: 8 March 2021
Key words:
Mental health care; people living with HIV;




© The Author(s), 2021. Published by
Cambridge University Press. This is an Open
Access article, distributed under the terms of
the Creative Commons Attribution-
NonCommercial-ShareAlike licence (http://
creativecommons.org/licenses/by-nc-sa/4.0),
which permits non-commercial re-use,
distribution, and reproduction in any medium,
provided the same Creative Commons licence
is used to distribute the re-used or adapted
article and the original article is properly cited.
The written permission of Cambridge
University Press must be obtained prior to any
commercial use.
The treatment gap for mental disorders in
adults enrolled in HIV treatment programmes
in South Africa: a cohort study using linked
electronic health records
Y. Ruffieux1 , O. Efthimiou1,2, L. L. Van den Heuvel3, J. A. Joska4, M. Cornell5,
S. Seedat3, J. P. Mouton5,6, H. Prozesky7, C. Lund8,9 , N. Maxwell5, M. Tlali5,
C. Orrell10,11, M.-A. Davies5,12, G. Maartens6 and A. D. Haas1
1Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; 2Department of Psychiatry,
University of Oxford, Oxford, UK; 3Department of Psychiatry, Faculty of Medicine and Health Sciences, University of
Stellenbosch, Cape Town, South Africa; 4Department of Psychiatry and Mental Health, HIV Mental Health Research
Unit, Neuroscience Institute, University of Cape Town, Cape Town, South Africa; 5Centre for Infectious Disease
Epidemiology & Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town,
South Africa; 6Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town,
South Africa; 7Division of Infectious Diseases, Department of Medicine, Stellenbosch University, Cape Town, South
Africa; 8Department of Psychiatry and Mental Health, Alan J Flisher Centre for Public Mental Health, University of
Cape Town, Cape Town, South Africa; 9Centre for Global Mental Health, King’s Global Health Institute, Health
Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King’s College
London, London, UK; 10Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine (IDM),
University of Cape Town, Cape Town, South Africa; 11Department of Medicine, University of Cape Town, Cape
Town, South Africa and 12Western Cape Provincial Department of Health, Cape Town, South Africa
Abstract
Aims. Mental disorders are common in people living with HIV (PLWH) but often remain
untreated. This study aimed to explore the treatment gap for mental disorders in adults fol-
lowed-up in antiretroviral therapy (ART) programmes in South Africa and disparities between
ART programmes regarding the provision of mental health services.
Methods. We conducted a cohort study using ART programme data and linked pharmacy
and hospitalisation data to examine the 12-month prevalence of treatment for mental
disorders and factors associated with the rate of treatment for mental disorders among
adults, aged 15–49 years, followed-up from 1 January 2012 to 31 December 2017 at one
private care, one public tertiary care and two pubic primary care ART programmes in
South Africa. We calculated the treatment gap for mental disorders as the discrepancy
between the 12-month prevalence of mental disorders in PLWH (aged 15–49 years) in
South Africa (estimated based on data from the Global Burden of Disease study) and
the 12-month prevalence of treatment for mental disorders in ART programmes. We cal-
culated adjusted rate ratios (aRRs) for factors associated with the treatment rate of mental
disorders using Poisson regression.
Results. In total, 182 285 ART patients were followed-up over 405 153 person-years. In 2017,
the estimated treatment gap for mental disorders was 40.5% (95% confidence interval [CI]
19.5–52.9) for patients followed-up in private care, 96.5% (95% CI 95.0–97.5) for patients fol-
lowed-up in public primary care and 65.0% (95% CI 36.5–85.1) for patients followed-up in
public tertiary care ART programmes. Rates of treatment with antidepressants, anxiolytics
and antipsychotics were 17 (aRR 0.06, 95% CI 0.06–0.07), 50 (aRR 0.02, 95% CI 0.01–0.03)
and 2.6 (aRR 0.39, 95% CI 0.35–0.43) times lower in public primary care programmes than
in the private sector programmes.
Conclusions. There is a large treatment gap for mental disorders in PLWH in South Africa
and substantial disparities in access to mental health services between patients receiving ART
in the public vs the private sector. In the public sector and especially in public primary care,
PLWH with common mental disorders remain mostly untreated.
Introduction
Mental illness is a leading cause of disease burden in Africa (Global Burden of Disease Study.
GDB Compare, 2015; Vos et al., 2015). In South Africa, mental disorders affect one in three
adults during their lifetime (Herman et al., 2009). The Global Burden of Disease (GBD) study
estimates a 12-month prevalence of mental disorders of 15% among adults of 15–49 years old
(Global Burden of Disease Collaborative Network, 2018).
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South Africa has the largest number of people living with HIV
(PLWH) globally. In 2019, there were 7.7 million PLWH in South
Africa, over 5 million of whom were receiving antiretroviral ther-
apy (ART) (Joint United Nations Programme on HIV/AIDS
(UNAIDS), 2020). Mental disorders are highly prevalent among
PLWH (Olley et al., 2003; Freeman et al., 2006; Myer et al.,
2008) and associated with suboptimal HIV treatment outcomes,
and increased mortality (Uthman et al., 2015; Haas et al.,
2020a, 2020b).
Early diagnosis and management of mental disorders not only
improves the quality of people with lived experience of mental ill-
ness, but may also prevent HIV disease progression, development
of drug resistance and HIV transmission (Safren et al., 2016).
Despite the impact of mental health at all levels of the HIV treat-
ment cascade, there is a large ‘treatment gap’ for mental disorders
in South Africa (Docrat et al., 2019). The treatment gap refers to
the difference between the prevalence of a disorder and the pro-
portion of people who receive treatment for that disorder
(Kohn et al., 2004).
Globally, estimates of the treatment gap for mental disorders
in the general population range from 50 to over 90% (Abas and
Broadhead, 1997; Demyttenaere et al., 2004; Kohn et al., 2004;
Mogga et al., 2006; Seedat et al., 2008; Docrat et al., 2019).
Previous study on the treatment gap in mental health care has
focused on the general population. To the best of our knowledge,
there are no data on the treatment gap for mental disorders in
PLWH in low- and middle-income countries.
This study aims to quantify the treatment gap for mental dis-
orders among PLWH who enrolled in HIV care at public and pri-
vate sector ART programmes in South Africa and to examine




We conducted a cohort study using routine HIV programme data
covering the period from 1 January 2004 to 31 December 2017,
linked pharmacy and hospitalisation data covering the period
from 1 January 2012 to 31 December 2017 and disease prevalence
estimates from the GBD 2017 study (Institute for Health Metrics
and Evaluation (IHME), 2018) to examine mental health service
utilisation among PLWH followed under ART at four South
African HIV treatment programmes. The primary exposure of
interest was the type of health care offered at HIV treatment pro-
grammes defined as public primary care, public tertiary care or
private care. We followed patients from baseline (the date of
ART initiation or 1 January 2012, whichever occurred later) to
their last clinical visit or their 50th birthday, whichever occurred
first. Table 1 provides an overview of outcome measures, data
source and analytical procedures.
Setting
We examined the utilisation of mental health services at three
public and one private sector HIV treatment programmes in
South Africa. The Gugulethu Community Health Centre
(CHC), the Khayelitsha ART programme and the Tygerberg
Academic Hospital are public sector HIV treatment programmes
providing ART according to national treatment guidelines
(Meintjes et al., 2017). The three programmes are situated in
Cape Town in South Africa. Gugulethu and Khayelitsha are pub-
lic primary care programmes located in townships and Tygerberg
is a public tertiary care facility which manages patients with more
severe illness. In Cape Town’s public sector health care system,
primary care facilities are the first point of care for individuals
with common and stable, serious mental disorders. Individuals
with serious mental disorders requiring either admission or
more specialised services are referred to and managed at second-
ary and tertiary care facilities (Western Cape Government, 2019).
The Aid for AIDS (AfA) programme is a private sector HIV pro-
gramme for insured and employed people in South Africa. HIV
treatment is provided by private medical practitioners and specia-
lists following national treatment guidelines (Meintjes et al.,
2017). In the private sector, mental health care is provided by
independent general practitioners, psychiatrists and psychologists
and private inpatient mental health facilities. Involuntary admis-
sions are handled by state services.
Estimation of the prevalence of mental disorders in PLWH
We calculated the 12-month prevalence of mental disorders in
PLWH in South Africa in each year by combining, through a set
of equations (Appendix A), estimates for the prevalence of HIV
and mental disorders in adults (aged 15–49 years) in the general
South African population from the GBD 2017 study (Institute
for Health Metrics and Evaluation (IHME), 2018) and, a literature
estimate for excess mental disorders in HIV-positive compared
with HIV-negative populations (Adewuya et al., 2007).
Mental health service utilisation among PLWH receiving ART
Measures
We estimated three measures of mental health service utilisation
among PLWH: (1) rates of treatment for mental disorders, (2)
adjusted rate ratios (aRRs) for treatment of mental disorders
and (3) the 12-month prevalence of treatment for mental disor-
ders (Table 1). We calculated these measures for three types of
treatment: (1) pharmacological treatment of mental disorders,
(2) inpatient treatment of mental disorders and (3) any treatment
of mental disorders (either pharmacological or inpatient). We had
no data on non-pharmacological outpatient treatments such as
psychotherapy and did not consider these therapies in our
analysis.
We defined pharmacological mental health treatment as treat-
ment with antipsychotics (anatomical therapeutic chemical
[ATC]: code N05A), anxiolytics (N05B), antidepressants
(N06A), psychostimulants (N06B) or a combination of psychiatric
drugs (N06C). We defined inpatient treatment of a mental dis-
order as hospitalisation at a psychiatric health facility for any rea-
son, or as hospitalisation at any health facility for the treatment of
an organic mental disorder (International Statistical Classification
of Diseases and Related Health Problems, 10th revision [ICD-10]
codes F04–F06.1, F06.3–F07.0, F09), a psychotic disorder (F20–
F29), a mood disorder (F30–F39), an anxiety disorder (F40–
F48) or any other mental disorder (F50–F99, G47–G47.29,
G47.4–G47.9, R40–R40.4, R45–R49, Z03.2, Z04.6–Z04.72, Z13.4,
Z64, Z81, Z81.8, Z86.5 or Z86.59). ICD-10 code descriptions
are provided in online Supplementary Table S1. We estimated
aRRs for specific categories of inpatient treatments (psychotic,
mood or anxiety disorder) and pharmacological treatments (anti-
psychotics, anxiolytics or antidepressants).
2 Y. Ruffieux et al.
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Data sources
We extracted routine HIV programme data from four treatment
programmes from the International epidemiology Databases to
Evaluate AIDS (IeDEA) (Chammartin et al., 2020). These data
contain clinical, sociodemographic and administrative data of
PLWH followed under ART. The Western Cape Provincial
Health Data Centre (PHDC) linked HIV programme data from
public sector ART programmes to hospitalisation and pharmacy
dispensing records from most public sector health facilities in
the Western Cape Province using unique person identifiers
(Boulle et al., 2019). The AfA programme linked private sector
HIV programme data to hospitalisation and pharmacy claims
data from the medical insurance fund claim database (Leisegang
et al., 2009; Karamchand et al., 2016). The list of variables that
we used from each of these data sources is shown in Table 1.
Inclusion criteria
We included PLWH aged 15–49 years at baseline who enrolled in
the Gugulethu, Khayelitsha, Tygerberg or AfA ART programmes,
and had at least one follow-up visit after baseline and between 1
January 2012 and 31 December 2017.
Statistical analysis
We calculated rates of treatment of mental disorders for inpatient,
pharmacological or any treatment in each calendar year and by
type of care as the number of treatment events divided by the
number of person-years (py) under follow-up. We treated each
hospital admission as a separate event. We treated pharmacy
refills for psychiatric medication which occurred in the same
year as one event. We calculated aRR for factors associated with
the incidence of inpatient treatment of a psychotic, mood, anxiety
Table 1. Overview of outcome measures, data source and analytical procedures
Outcome measure Stratification Estimation Data sources





By year Notation: α( y) defined as the 12-month
prevalence of mental disorders in PLWH in
year y
Equations for estimation are provided in
Appendix A
• Estimates for the prevalence of HIV
and mental disorders in adults
aged 15–49 years in South Africa
from the Global Burden of Diseases
study (IHME, 2018)
• A literature estimate for excess
mental disorders in HIV-positive
compared with HIV-negative
populations (Adewuya et al., 2007)




For (1) pharmacological, (2) inpatient
or (3) any treatment by year and type
of care
Number of treatment events divided by
person-years under follow-up
• HIV programme data
o Source: IeDEA (Chammartin
et al., 2020)
o Variables: Sex, type of care, date
of birth, ART initiation, death,
transfer, clinic visit dates, CD4
cell count
• Pharmacy data
o Sources: Dispensing records
from PHDC (public care) (Boulle
et al., 2019) and claim data from
the medical insurance fund
claim database (private care)
o Variables: Date and ATC code of
prescribed medication
• Hospital data
o Sources: Hospital discharge
records from PHDC (public care)
(Boulle et al., 2019) and hospital
claim data from the medical
insurance fund claim database
(private care)
o Variables: Admission and






Comparing (1) the incidence of
inpatient treatment of psychotic,
mood, anxiety or any mental disorders,
and (2) the incidence of
pharmacological treatment with
antipsychotics, antidepressants,
anxiolytics or any psychiatric
medication by type of care, sex, age
and CD4 cell count
Multivariable Poisson regression adjusted






For (1) pharmacological, (2) inpatient
or (3) any treatment by year and type
of care
Pt(y, c) = Tt(y, c)N(y, c)
where Tt( y, c) is the number of patients in
type of care c who received treatment for a
mental disorder of type t in year y, and N( y,
c) is the total number of completed
12-month intervals in year y in type of care c





By year and type of care d(y, c) = 1− Pany ( y, c)
a(y)
where Pany( y, c) is the 12-month prevalence
of any treatment for a mental disorder in
year y and type of care c
• The estimated 12-month
prevalence of mental disorders in
PLWH, i.e. α( y)
• The estimated 12-month
prevalence of any treatment for a
mental disorder in PLWH, i.e.
Pany( y, c)
PLWH, people living with HIV; ART, antiretroviral therapy; IeDEA, International epidemiology Databases to Evaluate AIDS; PHDC, Western Cape Provincial Health Data Centre.
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or any mental disorder, and pharmacological treatment with anti-
psychotics, antidepressants, anxiolytics or any psychiatric medica-
tion using Poisson regression. Models were adjusted for type of
care, sex, age, year and CD4 cell count at baseline. Age was treated
as a categorical variable (15–24 years, 25–34 years, 35–44 years
and 45–49 years). CD4 cell count was measured at baseline
(0–99 cells/μl, 100–199 cells/μl, 200–349 cells/μl, 350–499 cells/
μl, ≥500 cells/μl and missing). Age and year were modelled as
time-varying covariates. We used robust sandwich estimators of
the standard error to account for clustering of data by patients
(Zeileis, 2006). We imputed missing data for ICD-10 codes for
unclassified hospital admissions (ICD-10 code F99 or missing)
using multiple imputation with chained equations (van Buuren
and Groothuis-Oudshoorn, 2011) and pooled the analyses from
five sets of imputations using Rubin’s rule (Little and Rubin,
2002). To estimate the 12-month prevalence of treatment for
mental disorders, we split follow-up time into 12-month intervals,
assigned each interval to the calendar year in which most days of
the interval occurred and calculated the proportion of patients
who had received treatment for a mental disorder (pharmaco-
logical, inpatient or any) during each completed interval
(Table 1). We calculated 95% confidence intervals (CIs) for the
12-month prevalence of treatment for mental disorders based
on a binomial distribution.
Estimation of the treatment gap for mental disorders in PLWH
receiving ART
We calculated the treatment gap for mental disorders δ( y, c) in
year y and type of care c, using the following equation:
d(y, c) = 1− Pany(y, c)
a(y)
,
where Pany( y, c) is the 12-month prevalence of any treatment
(inpatient or pharmacological) for a mental disorder in year y
and type of care c, and α( y) is the prevalence of mental disorders
in PLWH in South Africa in year y. We expressed the treatment
gap as a percentage throughout our analysis. All statistical ana-
lyses were performed using the R Project for statistical computing
software.
Results
The prevalence of mental disorders in PLWH in South Africa
We estimated that in 2012, 39.5% (95% CI 29.2–50.0) of PLWH
(15–49 years) in South Africa had a mental disorder. The preva-
lence was 39.4% (95% CI 29.1–49.8) for 2013, 39.3% (95% CI
29.0–49.7) for 2014, 39.3% (95% CI 28.9–49.5) for 2015, 39.2%
(95% CI 29.0–49.4) for 2016 and 39.1% (95% CI 29.0–49.3) for
2017.
Characteristics of PLWH receiving ART
Of the 363 384 people included in the IeDEA databases of the
Gugulethu, Khayelitsha, Tygerberg and AfA ART programmes,
182 285 (50.2%) met our inclusion criteria: 140 322 (77.0%)
were from the private sector AfA programme, 39 381 (21.6%)
from public primary care programmes and 2582 (1.4%) from
the public tertiary care programme (Table 2). Most patients
were female (67.5%), the median age at ART initiation was 35
years (interquartile range [IQR] 31–41), median CD4 at ART ini-
tiation was 238 cells/μl (IQR 127–380) and median CD4 at base-
line was 359 cells/μl (IQR 219–548). Patients in the private sector
programme initiated ART at an older age and at a higher CD4 cell
count than patients in the public sector programmes. CD4 at
baseline was higher in the private sector than in the public sector
programmes.
The 12-month prevalence of treatment for mental disorders in
PLWH receiving ART
Figure 1 shows the 12-month prevalence of inpatient, pharmaco-
logical and any (inpatient or pharmacological) treatment for a
mental disorder in private care, public primary care and public
tertiary care ART programmes. The 12-month prevalence of
inpatient, pharmacological or any treatment for a mental disorder
was highest in private care, followed by public tertiary care, and
lowest in public primary care. In the private sector, the
12-month prevalence of inpatient and pharmacological mental
health treatment was higher in women than in men (online
Supplementary Fig. S1).
The mental health treatment gap in PLWH receiving ART
Figure 2 and online Supplementary Table S2 show the estimated
treatment gap for mental disorders in private care, public primary
care and public tertiary care ART patients. In private care, the
treatment gap decreased from 63.6% (95% CI 50.5–71.2) in
2013 to 42.7% (95% CI 22.3–54.7) in 2014 (Fig. 2). In public pri-
mary care, the treatment gap decreased slightly from 97.4% (95%
CI 96.3–98.1) in 2012 to 96.5% (95% CI 95.0–97.5) in 2017. In
public tertiary care, the treatment gap decreased from 82.8%
(95% CI 74.4–88.4) in 2012 to 65.0% (95% CI 36.5–85.1) in 2017.
Differences in mental health treatment rates by type of care
Online Supplementary Table S3 shows the yearly number of treat-
ment events, py at risk and crude rates of treatment for mental
disorders among patients followed-up in the ART programmes.
Figure 3 shows aRRs comparing rates of treatment for mental dis-
orders between patients enrolled in private care, public primary
care and public tertiary care. The rate of inpatient treatment
was 25 times (aRR 0.04, 95% CI 0.03–0.05) lower for mood dis-
orders, 14 times lower (aRR 0.07, 95% CI 0.04–0.14) for anxiety
disorders and about two times higher (aRR 1.80, 95% CI 1.31–
2.47) for psychotic disorders in patients enrolled in public pri-
mary care compared to private care. In patients enrolled in public
tertiary care compared to private care, the rate of inpatient treat-
ment was five times lower (aRR 0.20, 95% CI 0.11–0.36) for mood
disorders, less than two times lower (aRR 0.59, 95% CI 0.22–1.6)
for anxiety disorders, but seven times higher (aRR 7.26, 95% CI
3.66–14.41) for psychotic disorders. The rates of treatment with
antidepressants, anxiolytics and antipsychotics were 17 (aRR
0.06, 95% CI 0.06–0.07), 50 (aRR 0.02, 95% CI 0.02–0.03) and
2.6 (aRR 0.38, 95% CI 0.35–0.42) times lower in patients enrolled
in public primary care than in private care. In patients enrolled in
public tertiary care compared to private care, the rates of treat-
ment with antidepressants (aRR 0.48, 95% CI 0.4–0.58) and
anxiolytics (aRR 0.16, 95% CI 0.12–0.21) were lower and the
rate of treatment with antipsychotics was higher (aRR 1.57, 95%
CI 1.27–1.93) (Table 3).
4 Y. Ruffieux et al.
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Patient characteristics associated with mental health
treatment rates
Women had a higher incidence of inpatient treatment for mood
(aRR 1.56, 95% CI 1.43–1.70), anxiety (aRR 2.21, 95% CI 1.75–
2.79) and any mental disorder (aRR 1.49, 95% CI 1.37–1.62)
than men (Table 3). Women were also more likely to receive
psychiatric medication than men with aRRs of 1.32 (95% CI
1.24–1.40) for antipsychotics, 1.49 (95% CI 1.45–1.53) for antide-
pressants and 1.60 (95% CI 1.55–1.64) for anxiolytics. Older age
was associated with a lower incidence of inpatient treatment for
any mental disorders and a higher incidence of pharmacological
treatment with antidepressants, anxiolytics and any psychiatric
medication. Higher baseline CD4 cell count was associated with
a lower incidence of inpatient treatment for a psychotic disorder
and with a slightly lower incidence of treatment with antipsycho-
tics and antidepressants (Table 3).
Discussion
Our study showed a large treatment gap for mental disorders in
PLWH who enrolled in ART programmes in South Africa. We
found substantial disparities in access to mental health services
between patients who receive ART in private v. public sector pro-
grammes. In 2017 the treatment gap for mental disorders in
PLWH was 96.5% in public primary care programmes, 65.0% in
the public tertiary care programme, and 40.5% in the private pro-
gramme. The rate of treatment with antidepressants, anxiolytics
and antipsychotics was 17, 50 and 2.6 times lower in the public
primary care programmes compared with the private programme.
We found considerable gender differences in mental health treat-
ment rates, with women being treated more often than men.
Our estimates for the treatment gap in mental disorders in
PLWH in South Africa are largely consistent with data from earl-
ier studies in the general population from various settings. A
meta-analysis of studies published between 1980 and 2003 esti-
mated that the global treatment gap was 58% for generalised anx-
iety and obsessive compulsive disorders, 56% for depression,
dysthymia and panic disorder, 50.2% for bipolar disorder and
32% for schizophrenia (Kohn et al., 2004). The World Health
Organization (WHO) World Mental Health Survey, conducted
between 2001 and 2003, reported a treatment gap for mental
health and substance use problems of 76% in less-developed
countries (Demyttenaere et al., 2004). The South African Stress
and Health Study (SASH), conducted between 2002 and 2004,
found that 74% of the people with anxiety disorder, mood dis-
order, substance use disorder or intermittent explosive disorder
received no mental health treatment in the year before the survey
(Seedat et al., 2008). Our estimates are also consistent with more
recent results from Docrat and colleagues. They estimated a 92%
treatment gap in South Africa’s public sector, with 86% of the
mental health care budget spent on inpatient care and only 8%
in the primary care setting (Docrat et al., 2019). The authors con-
cluded that South Africa’s public health care system prioritises
treating the most severe conditions, while non-severe mental dis-
orders are often overlooked. The high incidence of hospital




(n = 182 285)
Private carec
(n = 140 322)
Public primary carec
(n = 39 381)
Public tertiary carec
(n = 2582)
Characteristics at ART initiation
Female, n (%) 93 249 (66.5) 28 076 (71.3) 1757 (68.0) 123 082 (67.5)
Median [IQR] age, years 36 [32–41] 32 [28–38] 33 [28–39] 35 [31–41]
Median CD4 cells/μl [IQR] 254 [135–410] 193 [107–302] 162 [87–242] 238 [127–380]
Characteristics at baselined
Median years on ART [IQR] 0.3 [0.0–2.0] 0.0 [0.0–2.0] 1.2 [0.0–3.7] 0.1 [0.0–2.1]
Median [IQR] age, years 38 [33–43] 34 [29–39] 36 [30–41] 37 [32–42]
Median CD4 cells/μl [IQR]e 378 [229–571] 307 [184–454] 320 [189–493] 359 [219–548]
CD4 category at baselinee, n (%)
0–99 cells/μl 11 383 (8.1) 3381 (8.6) 265 (10.3) 15 029 (8.2)
100–199 cells/μl 14 075 (10.0) 4480 (11.4) 358 (13.9) 18 913 (10.4)
200–349 cells/μl 30 171 (21.5) 9224 (23.4) 668 (25.9) 40 063 (22.0)
350–499 cells/μl 26 364 (18.8) 5864 (14.9) 456 (17.7) 32 684 (17.9)
≥500 cells/μl 40 436 (28.8) 5519 (14.0) 563 (21.8) 46 518 (25.5)
Missing 17 893 (12.8) 10 913 (27.7) 272 (10.5) 29 078 (16.0)
ART, antiretroviral therapy; IQR, interquartile range.
aPatients with at least one follow-up visit between 1 January 2012 and 31 December 2017 were included.
bAll values in the table represent medians and interquartile ranges unless otherwise stated.
cPrivate care: AfA programme; public primary care: Gugulethu and Khayelitsha programmes; public tertiary care: Tygerberg Hospital.
dBaseline was defined as 1 January 2012 or date of ART initiation of the patient, whichever came second.
eThe CD4 cell count measurement closest to the baseline date, within a 6-month window (before or after).
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admission for psychotic disorders and the low rates of prescrip-
tions of antidepressants and anxiolytics in the primary care set-
ting provide further support for this conclusion.
The comparison of the rate of inpatient treatments between
public and private sector programmes has to be interpreted
with caution. According to the South African Mental Health
Care Act, all involuntary admissions are handled by state services
(Parliament of the Republic of South Africa, 2002). Our data did not
capture involuntary admissions of private care patients. Because
admissions for a psychotic disorder are often involuntary (Moosa
and Jeenah, 2008; Madala-Witbooi and Adeniyi, 2019), excess rates
of inpatient care for psychotic disorders in patients enrolled in public
compared to private sector ART programmes are likely to be overes-
timated. The large increase of inpatient care for psychotic disorders
in patients enrolled in public tertiary care may also reflect more
advanced HIV disease in these patients. Psychotic disorders second-
ary to HIV tend to occur at more advanced stages and the lower
baseline CD4 cell counts observed in public, particularly tertiary
care, programmes could align with this explanation (Owe-Larsson
et al., 2009). Furthermore, higher baseline CD4 cell counts were asso-
ciated with lower rates of treatment for psychotic disorders.
Our study showed substantial disparities in access to mental
health services between patients who receive ART in private v. public
sector programmes. We believe that the lack of resources allocated to
treating mental disorders in the public sector (Docrat et al., 2019) is
a major factor contributing to the large treatment gap in mental dis-
orders in public sector ART programmes. Disparities in mental
health treatment rates between the public and the private sector
might also reflect underlying socioeconomic differences between
the two patient populations attending public v. private care pro-
grammes. The public sector ART programmes Gugulethu and
Khayelitsha are situated in the most impoverished areas in Cape
Town, whereas the AfA programme is a private sector programme
for employed people with health insurance. We had no individual
patient data on socioeconomic status or related factors that could
influence access to care and did not adjust for these variables.
The higher inpatient treatment rates for anxiety and mood, but
not psychotic, disorders in women could represent a higher
prevalence of common mental disorders in women (Steel et al.,
2014; Kuehner, 2017). It could also result from differences in
healthcare-seeking behaviour between men and women or dis-
crimination against men in the health care system, for example
through a practitioner’s subconscious tendency to overlook psy-
chological distress in men (Smith et al., 2018). Lower inpatient
treatment rates and higher rates of pharmacological treatment,
excluding antipsychotics, in older age groups could potentially be
explained by younger individuals presenting with first episodes of
illness requiring more intensive investigations and interventions
compared to individuals with known or recurring conditions.
Our results must be considered in light of several limitations.
We found no estimates for the overall prevalence of psychiatric
disorders in PLWH in South Africa. We, therefore, estimated
the need for mental health treatment based on data from the
GBD (Institute for Health Metrics and Evaluation (IHME),
2018) and literature estimates (Adewuya et al., 2007).
Population-based surveys using structured diagnostic interviews
(Abas and Broadhead, 1997; Kebede et al., 2003; Demyttenaere
et al., 2004; Kohn et al., 2004; Mogga et al., 2006; Seedat et al.,
2008) provide more reliable estimates for the need of mental
health treatment than our study. We had no data on non-
pharmacological outpatient interventions such as psychotherapy
and could not consider these therapies when estimating the treat-
ment gap. We believe that this limitation could have led to a slight
over-estimation of the treatment gap, given poor access to psycho-
logical interventions, particularly in the public sector. Conversely,
psychiatric medication is sometimes used for indications not
related to mental health, for which reason we might have slightly
underestimated the treatment gap. Furthermore, we did not adjust
our estimates for underlying differences between different care
Fig. 1. 12-month prevalence of treatment for a mental disorder in patients aged
15–49 years followed-up in private care (AfA), public primary care (Gugulethu,
Khayelitsha), and public tertiary care (Tygerberg) antiretroviral therapy programs
programmes, 2012-2017. Patients who had been admitted for a mental disorder or
to a psychiatric health facility were considered to have received inpatient treatment
for a mental disorder. Patients who had received antipsychotics (Anatomical
Therapeutic Chemical [ATC] code N05A), anxiolytics (N05B), antidepressants
(N06A), psychostimulants (N06B) or psychiatric combination drugs (N06C) were con-
sidered to have received pharmacological treatment for a mental disorder. Patients
who received either inpatient or pharmacological treatment were considered to
have received any treatment for a mental disorder.
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Fig. 2. The treatment gap for mental disorders at private
care (AfA), public primary care(Gugulethu, Khayelitsha),
and public tertiary care (Tygerberg) antiretroviral ther-
apy programs, 2012-2017.
Fig. 3. Adjusted rate ratios comparing rates of treatment
for mental disorders by type of care. Rates of inpatient
treatment of psychotic, mood, anxiety, or any mental
disorder (top) and pharmacological treatment with anti-
psychotics, antidepressants, anxiolytics, or any psychi-
atric medication (bottom) are compared between
patients in public primary care (Gugulethu and
Khayelitsha), public tertiary care (Tygerberg), and a pri-
vate care (Aid for AIDS [AfA]) antiretroviral therapy pro-
grams, 2012-2017. The private care program was the
reference group. Incidence rate ratios were adjusted for
gender, current age, current year, and baseline CD4
cell count.
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Table 3. Adjusted rate ratios for factors associated with treatment for mental disorders in patients aged 15–49 years followed-up in private care, public primary care and public tertiary care ART programmes during
2012–2017a










Private care 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Public primary
1.80 (1.31–2.47) 0.04 (0.03–0.05) 0.07 (0.04–0.14) 0.12 (0.10–0.14) 0.38 (0.35–0.42) 0.06 (0.06–0.07) 0.02 (0.02–0.03) 0.09 (0.08–0.09)
Public tertiary 7.26 (3.66–14.41) 0.20 (0.11–0.36) 0.59 (0.22–1.60) 0.44 (0.29–0.69) 1.57 (1.27–1.93) 0.48 (0.40–0.58) 0.16 (0.12–0.21) 0.44 (0.39–0.51)
Sex
Male 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Female 0.86 (0.59–1.24) 1.56 (1.43–1.70) 2.21 (1.75–2.79) 1.49 (1.37–1.62) 1.32 (1.24–1.4) 1.49 (1.45–1.53) 1.60 (1.55–1.64) 1.43 (1.40–1.46)
Age, years
15–24 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
25–34 0.86 (0.40–1.85) 0.92 (0.75–1.13) 0.88 (0.52–1.51) 0.90 (0.73–1.10) 1.00 (0.85–1.18) 1.52 (1.37–1.68) 1.62 (1.45–1.80) 1.40 (1.30–1.51)
35–44 0.71 (0.33–1.53) 0.84 (0.69–1.03) 0.68 (0.40–1.15) 0.80 (0.66–0.98) 0.95 (0.81–1.12) 1.75 (1.58–1.94) 1.83 (1.64–2.04) 1.55 (1.44–1.67)
45–49 0.77 (0.34–1.74) 0.76 (0.61–0.94) 0.59 (0.34–1.04) 0.74 (0.60–0.91) 1.05 (0.88–1.24) 2.06 (1.86–2.29) 2.05 (1.84–2.29) 1.76 (1.63–1.90)
Baseline CD4 cell count, cells/μla
0–99 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
100–199 0.79 (0.46–1.35) 0.99 (0.84–1.17) 1.56 (1.02–2.40) 0.92 (0.79–1.07) 0.95 (0.85–1.06) 0.95 (0.9–1) 1.01 (0.95–1.08) 0.97 (0.93–1.01)
200–349 0.63 (0.38–1.05) 1.01 (0.87–1.17) 1.37 (0.94–2.01) 0.89 (0.78–1.02) 0.87 (0.79–0.96) 0.93 (0.88–0.97) 0.99 (0.94–1.05) 0.94 (0.91–0.98)
350–499 0.38 (0.22–0.67) 0.92 (0.79–1.07) 1.16 (0.79–1.73) 0.78 (0.68–0.90) 0.89 (0.80–0.99) 0.90 (0.85–0.94) 0.99 (0.93–1.05) 0.93 (0.89–0.96)
≥500 0.49 (0.26–0.93) 1.00 (0.86–1.15) 1.38 (0.95–2.01) 0.85 (0.75–0.97) 0.88 (0.80–0.97) 0.94 (0.90–0.99) 1.00 (0.95–1.06) 0.94 (0.91–0.98)
Missing 0.44 (0.26–0.74) 0.89 (0.76–1.03) 0.93 (0.63–1.37) 0.76 (0.67–0.87) 0.99 (0.90–1.09) 0.88 (0.84–0.92) 0.98 (0.93–1.04) 0.89 (0.86–0.93)
aPatients with at least one follow-up visit between 1 January 2012 and 31 December 2017 were included.
bData are aRRs with 95% CIs in parenthesis. Rate ratios were adjusted for ART programme, sex, age, baseline CD4 cell count and year.
cRepeated hospital admissions were treated as separate events. The incidence of inpatient treatment for mental disorders was modelled as count data.
dPharmacy refills for psychiatric medication which occurred in the same year were counted as one event. The incidence of pharmacological treatment for a mental disorder was modelled as a binary outcome.
ePsychotic disorder (ICD-10 codes F20–F29), mood disorder (F30–F39), anxiety disorder (F40–F48) and any mental disorder (F20–F99); antipsychotics (ATC code N05A), anxiolytics (N05B), antidepressants (N06A), any psychiatric medication
(antipsychotics, anxiolytics, antidepressants, psychostimulants [N06B] or psychiatric combination drugs [N06C]).
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settings. Mental disorders might be more common in public sec-
tor patients who tend to have more socioeconomic stressors.
Patients in tertiary care are likely to have more comorbidities and
thus may have a higher risk of mental disorders. Because we
could not account for these underlying differences, we may have
overestimated the treatment gap in private care and underestimated
the treatment gap in tertiary care. We could not track patients
transferring between ART programmes. Thus we may have slightly
underestimated the uncertainty of our estimates because we could
not adjust for possible clustering of data within individuals.
Finally, we cannot rule out the possibility that observed differences
between programmes may have at least partly resulted from hetero-
geneity of data sources and data quality.
An important strength of our study is that we used medical
records to estimate mental health treatment utilisation rates. Most
previous studies on the treatment gap relied on self-report data
(Abas and Broadhead, 1997; Kebede et al., 2003; Demyttenaere
et al., 2004; Kohn et al., 2004; Mogga et al., 2006; Seedat et al.,
2008). Users of mental health services might underreport service
utilisation due to mental health stigma (Furnham, 1986;
Thornicroft et al., 2007). A further strength of our study is that
we could account for mental health treatment received outside
the HIV treatment setting because we linked public and private sec-
tor ART programme data to province-wide and private data on
mental health treatment. Finally, the inclusion of data from public
primary care, public tertiary care and private care settings adds to
the robustness and generalisability of our findings.
The integration of evidence-based interventions for diagnosing
and managing mental disorders in primary care ART pro-
grammes holds great promise for closing the treatment gap in
PLWH (Remien et al., 2019). This could lead to an improvement
of outcomes across the treatment cascade. WHO and the South
African government have published guidelines for managing
mental disorders in non-specialised settings (World Health
Organization, 2016; Department of Health of the Republic of
South Africa, 2020). Our study suggests that the implementation
of mental health services in primary care ART programmes is
inconsistent. Continued efforts to close the treatment gap for people
with mental disorders are needed. Strategies to strengthen task-
shifting, training and capacitation of primary health care staff,
and models of referral and stepped-care will be crucial to closing
the treatment gap (Bhana et al., 2019; Petersen et al., 2019).
Conclusion
There is a large treatment gap for mental disorders in PLWH in
South Africa and substantial disparities in access to mental health
service between patients receiving care in the public vs the private
sector. In the public sector and especially in public primary care,
PLWH with common mental disorders remain mostly untreated.
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Appendix A: Estimation of the prevalence of mental
disorders (MD) in people living with HIV (PLWH) and the
treatment gap for MD
Estimation of the prevalence of MD in PLWH
Our target quantity of interest is α( y) = Py(MD + | HIV + ), i.e. the prevalence
of MD in PLWH in a given year y. We define β( y) = Py(MD + | HIV− ) as the
prevalence of MD in HIV-negative people in year y. We have data on the fol-
lowing quantities, with associated 95% confidence intervals (CIs):
• the prevalence of MD in the general population in year y, pm,y = Py(MD + ),
• the prevalence of HIV in the general population in year y, ph,y = Py(HIV + ),
• the odds ratio for the prevalence of MD in HIV-positive compared to
HIV-positive populations in year y
r(y) = Py(MD+ | HIV+ )/{1− Py(MD+ | HIV+ )}
Py(MD+ | HIV− )/{1− Py(MD+ | HIV− )} .
We obtain the following system of two equations, which we will solve for α
( y) and β( y):
pm,y = a(y)ph,y + b(y)(1− ph,y) (A1)
r(y) = a(y)/(1− a(y))
b(y)/(1− b(y)) (A2)
Equation (A1) results from the total probability rule, and leads to β( y) =
( pm,y− α( y)ph,y)/ (1− ph,y). Inserting this into (A2), we obtain:
( ph,yr(y)− ph,y)a(y)2 + ( ph,y + pm,y − 1− ph,yr(y)
− pm,yr(y))a(y)+ pm,yr(y) = 0
If r( y) = 1, then α( y) = β( y) = pm,y. We assume that r( y)≠ 1, i.e. that r( y) is
not exactly 1. Our desired α( y) is a solution to this second-degree equation.
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Setting a = ph,yr( y)− ph,y, b = ph,y + pm,y− 1− ph,yr( y)− pm,yr( y), c = pm,yr







We discard the other solution to the second-degree equation, as it does not
lie between 0 and 1.
Estimation of the treatment gap for MD and 95% CI
The treatment gap for MD in PLWH followed-up on antiretroviral therapy
(ART) is estimated as
d(y, c) = 1− Pany( y, c)
a(y)
(A4)
where Pany( y, c) is the 12-month prevalence of any treatment for MD
(inpatient or pharmacological) in year y and type of care c. To obtain a 95%
CI for α( y), we use a sampling method. Specifically, we assume that pm,y
and ph,y follow beta distributions, with parameters calibrated so that the
2.5%- and 97.5%-quantiles of the distributions match the bounds of their
respective 95% CIs. We assume that log (r( y)) follows a normal distribution,
with similarly calibrated mean and variance, and that Pany( y, c) follows a
binominal distribution Binom(P̂any(y, c), N( y, c)) where P̂any(y, c) is the
observed 12-month prevalence of treatment for MD and N( y, c) is the number
of patients at risk in year y and in type of care c.
We independently simulated a large sample of values (N = 100 000) for pm,y,
ph,y, r( y) and Pany( y, c) based on the distributions described above, thereby gen-
erating a sample of values for α( y) using (A3) and δ( y, c) using (A4). The
bounds of the 95% CI for δ( y, c) are estimated as the 2.5%- and 97.5%-quantiles
of the sample for δ( y, c).
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